Spatial analysis of advanced-stage ovarian cancer mortality in California

被引:27
|
作者
Bristow, Robert E. [1 ,2 ]
Chang, Jenny [3 ]
Ziogas, Argyrios [3 ]
Gillen, Daniel L. [2 ,4 ]
Bai, Lu [4 ]
Vieira, Veronica M. [4 ,5 ]
机构
[1] Univ Calif Irvine, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Orange, CA 92717 USA
[2] Univ Calif Irvine, Med Ctr, Ctr Comprehens Canc, Orange, CA 92717 USA
[3] Univ Calif Irvine, Sch Med, Dept Epidemiol, Irvine, CA 92717 USA
[4] Univ Calif Irvine, Sch Med, Dept Stat, Irvine, CA 92717 USA
[5] Univ Calif Irvine, Sch Med, Program Publ Hlth, Irvine, CA 92717 USA
基金
美国国家卫生研究院;
关键词
geographic location; ovarian cancer; TREATMENT GUIDELINES; REGIONAL-VARIATION; CARE; WOMEN; DISPARITIES; SURVIVAL; SURGERY; TRENDS; IMPACT; CHEMOTHERAPY;
D O I
10.1016/j.ajog.2015.01.045
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: We sought to determine the impact of geographic location on advanced-stage ovarian cancer mortality in relation to adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines and hospital case volume. STUDY DESIGN: This was a retrospective observational cohort study of patients diagnosed with stage IIIC/IV epithelial ovarian cancer (Jan. 1, 1996, through Dec. 31, 2006) identified from the California Cancer Registry. Generalized additive models were created to assess the effect of spatial distributions of geographic location, demographic characteristics, disease-related variables, adherence to NCCN guidelines, and hospital case volume, with simultaneous smoothing of geographic location and adjustment for confounding variables. RESULTS: A total of 11,765 patients were identified. Twelve of the 378 hospitals (3.2%) were high-volume hospitals (HVH) (>= 20 cases/y) and cared for 2112 patients (17.9%). For all patients, the median distance to an HVH was 22.7 km/14.1 miles and 80% were located within 79.6 km/49.5 miles of an HVH. Overall, 45.4% of patients were treated according to NCCN guidelines. The global test for location revealed that geographic position within the state was significantly correlated with ovarian cancer mortality after adjusting for other variables (P < .001). Distance to receive care >= 32 km/20 miles was protective against mortality (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.79-0.93), while distance from an HVH >= 80 km/50 miles was associated with an increased risk of death (HR, 1.13; 95% CI, 1.03-1.23). The effects of geographic predictors were attenuated when nonadherence to NCCN guidelines (HR, 1.25; 95% CI, 1.18-1.32) and care at an HVH (HR, 0.87; 95% CI, 0.81-0.93) were introduced into the model. CONCLUSION: Geographic location is a significant predictor of advanced-stage ovarian cancer mortality and the effect is primarily related to the likelihood of receiving NCCN guideline adherent care and treatment at an HVH.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status
    Bristow, Robert E.
    Chang, Jenny
    Ziogas, Argyrios
    Anton-Culver, Hoda
    Vieira, Veronica M.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (01) : 60 - 67
  • [2] Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California
    Long, Beverly
    Chang, Jenny
    Ziogas, Argyrios
    Tewari, Krishnansu S.
    Anton-Culver, Hoda
    Bristow, Robert E.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2015, 212 (04) : 468.e1 - 468.e9
  • [3] The "Definitive" Trial of Surgical Cytoreduction in Advanced-Stage Ovarian Cancer
    Naik, Raj
    Spirtos, Nick
    Pomel, Christophe
    Bristow, Rob
    Chi, Dennis
    Vergote, Ignace
    Donovan, Jenny
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (04) : 588 - 591
  • [4] Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer
    LaFargue, Christopher J.
    Handley, Katelyn F.
    Fleming, Nicole D.
    Nick, Alpa M.
    Chelariu-Raicu, Anca
    Fellman, Bryan
    Castellano, Tara
    Ogasawara, Aiko
    Hom-Tedla, Marianne
    Blake, Erin A.
    da Costa, Alexandre A. B. A.
    Crim, Aleia K.
    Rauh-Hain, Alejandro
    Westin, Shannon N.
    Coleman, Robert L.
    Matsuo, Koji
    Baiocchi, Glauco
    Hasegawa, Kosei
    Moore, Kathleen
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2022, 165 (01) : 82 - 89
  • [5] Role of lymphadenectomy in advanced-stage ovarian cancer: a meta-analysis
    Ronsini, Carlo
    Pasanisi, Francesca
    Andreoli, Giada
    De Franciscis, Pasquale
    Cobellis, Luigi
    Vizzielli, Giuseppe
    Restaino, Stefano
    Romeo, Paola
    Palmara, Vittorio
    Cianci, Stefano
    FRONTIERS IN SURGERY, 2024, 11
  • [6] Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer
    Khalafi-Nezhad, Abolfazl
    Ebrahimi, Vahid
    Ahmadpour, Fatemeh
    Momtahan, Mozhdeh
    Robati, Minoo
    Saraf, Zahra
    Ramzi, Mani
    Jowkar, Zahra
    Ghaffari, Parvin
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 1447 - 1456
  • [7] Spatial assessment of advanced-stage diagnosis and lung cancer mortality in Brazil
    Nunes de Lima, Kalya Yasmine
    Cancela, Marianna de Camargo
    de Souza, Dyego Leandro Bezerra
    PLOS ONE, 2022, 17 (03):
  • [8] Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer
    Lee, Yong Jae
    Chung, Young Shin
    Lee, Jung-Yun
    Nam, Eun Ji
    Kim, Sang Wun
    Kim, Sunghoon
    Kim, Young Tae
    CANCER MEDICINE, 2019, 8 (02): : 564 - 571
  • [9] Can advanced-stage ovarian cancer be cured?
    Narod, Steven
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (04) : 255 - 261
  • [10] The Influence of "Omental Cake" Presence on the Completeness of Cytoreduction in Advanced-stage Ovarian Cancer
    Bacalbasa, Nicolae
    Diaconu, Camelia
    Iliescu, Laura
    Savu, Cornel
    Bratu, Ovidiu Gabriel
    Bolca, Ciprian
    Cretoiu, Dragos
    Filipescu, Alexandru
    Dima, Simona
    Balalau, Cristian
    Balescu, Irina
    IN VIVO, 2020, 34 (04): : 2187 - 2191